Abnormal Immune Cell Function May Lead to Crohn’s Disease

What To Know

A Mount Sinai-led study published in Science Immunology reports that a specific group of intestinal immune cells — γδ intraepithelial lymphocytes (γδ IELs) — are reduced before inflammation begins in a mouse model that resembles Crohn’s disease.

The researchers link early loss and dysfunction of these γδ IELs to impaired barrier surveillance and unchecked pro-inflammatory IEL activity in the lower small intestine. The team also compared their timeline to previous patient biopsy findings and suggests that loss of γδ IELs might serve as a predictive biomarker for relapse or treatment response.

The article notes the idea that therapies to restore or boost γδ IEL function could be explored as a way to maintain remission or prevent disease in susceptible people. This report summarizes preclinical/basic-science findings rather than a clinical trial or new approved treatment.

It highlights mechanisms (immune-pathway dysregulation) that could guide future biomarker work and drug development.